Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,053 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Allergic Contact Dermatitis
Interventions: Dupilumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: FMX114, Vehicle; Drug · Other
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Miami, Florida • Miramar, Florida • Sugarloaf, Pennsylvania

Conditions: Hereditary Angioedema
Interventions: C1 Esterase Inhibitor, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 6 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 17
States / cities: Granada Hills, California • Weston, Florida • Atlanta, Georgia + 14 more

Conditions: Chronic Pruritus, Atopic Dermatitis
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 28
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 23 more

Conditions: Dermatitis, Atopic
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years to 54 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 64
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 53 more

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment; Drug
Lead sponsor: Clinical Research Center of the Carolinas; Other
Eligibility: 2 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hereditary Angioedema
Interventions: Ruconest; Biological
Lead sponsor: Bernstein Clinical Research Center; Other
Eligibility: 14 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama • Cincinnati, Ohio

Conditions: Atopic Dermatitis
Interventions: Bleach Bath and Moisturizers; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 8 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab SAR231893, Placebo, non sedating H1-antihistamine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 80 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more

Conditions: Atopic Dermatitis
Interventions: DS107, Placebo; Drug
Lead sponsor: DS Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 26
States / cities: Birmingham, Alabama • Huntington Beach, California • Los Angeles, California + 22 more

Conditions: Angioneurotic Edema
Interventions: HOE-140, Placebo; Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Conjunctivitis, Atopic Dermatitis
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Irvine, California • Palo Alto, California • Pasadena, California + 12 more

Conditions: Adverse Pregnancy Outcomes, Atopic Dermatitis
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 12,343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Tralokinumab; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 12 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 29
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 24 more

Conditions: Atopic Dermatitis
Interventions: KHK4083, Placebo; Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Huntington Beach, California • Irvine, California • Los Angeles, California + 10 more

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Interventions: IMG-007, Placebo; Drug
Lead sponsor: Inmagene LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 16
States / cities: Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more

Conditions: Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum, Health Controls Without Atopy
Interventions: Xolair; Biological
Lead sponsor: National Jewish Health; Other
Eligibility: 16 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atopic Dermatitis
Interventions: PR022; Drug
Lead sponsor: Realm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: RVT-501 0.5% topical ointment; Drug
Lead sponsor: Dermavant Sciences GmbH; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 12
States / cities: Anniston, Alabama • Irvine, California • Jacksonville, Florida + 7 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Cyclosporine A; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis (AD)
Interventions: BFB759, Placebo; Biological · Drug
Lead sponsor: Bluefin Biomedicine, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 48
States / cities: Phoenix, Arizona • Encino, California • Huntington Beach, California + 40 more

Conditions: Angioedema, Angioedemas, Hereditary, Urticaria, Mastocytosis, ACE Inhibitor-Induced Angioedema, C1 Inhibitor Deficiency, Systemic Mastocytoses, Indolent Systemic Mastocytosis
Interventions: Venipuncture; Diagnostic Test
Lead sponsor: Foundation For Rare Disease Research; Other
Eligibility: 12 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Hereditary Angioedema, HAE, Prophylaxis
Interventions: BCX7353; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 39 more

Conditions: Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Interventions: ATI-045, Placebo; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 53
States / cities: Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more

Search by objective public record fields.

The Effects of Dupilumab on Allergic Contact Dermatitis

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)

The Effect of Diluted Sodium Hypochlorite Solution and Moisturizers on Skin Barrier Function in Atopic Dermatitis

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema

Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Angioedema Biomarker Research Study

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis